# reload+after+2024-01-20 20:43:45.394961
address1§45 Sidney Street
city§Cambridge
state§MA
zip§02139
country§United States
phone§617 374 7580
website§https://www.blueprintmedicines.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and Fisogatinib. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
fullTimeEmployees§661
companyOfficers§[{'maxAge': 1, 'name': 'Ms. Kathryn  Haviland', 'age': 47, 'title': 'President, CEO & Director', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 1167606, 'exercisedValue': 0, 'unexercisedValue': 4641}, {'maxAge': 1, 'name': 'Mr. Alexis A. Borisy A.M.', 'age': 51, 'title': 'Co-Founder & Director', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 50000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael  Landsittel', 'age': 51, 'title': 'Chief Financial Officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 785358, 'exercisedValue': 0, 'unexercisedValue': 1612512}, {'maxAge': 1, 'name': 'Ms. Christina  Rossi', 'age': 46, 'title': 'Chief Operating Officer', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 875217, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Tracey L. McCain Esq.', 'age': 55, 'title': 'Executive VP, Chief Legal & Compliance Officer and Secretary', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 764901, 'exercisedValue': 0, 'unexercisedValue': 888550}, {'maxAge': 1, 'name': 'Dr. Fouad  Namouni M.D.', 'age': 54, 'title': 'President of Research & Development', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 916399, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Ariel  Hurley', 'age': 49, 'title': 'Senior VP, Finance & Principal Accounting Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Christopher K. Murray Ph.D.', 'age': 59, 'title': 'Senior VP of Technical Operations and Chief Technical Operations & Quality Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 338367, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Percy H. Carter M.B.A., Ph.D.', 'age': 52, 'title': 'Chief Scientific Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 761150, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Jenna  Cohen', 'title': 'Senior Director & Head of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§2
boardRisk§8
compensationRisk§5
shareHolderRightsRisk§7
overallRisk§6
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.728
priceToSalesTrailing12Months§23.328531
currency§USD
dateShortInterest§1702598400
forwardEps§-5.59
pegRatio§0.11
exchange§NMS
quoteType§EQUITY
shortName§Blueprint Medicines Corporation
longName§Blueprint Medicines Corporation
firstTradeDateEpochUtc§1430400600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§ff898492-23d6-3cda-8698-a93cfd1e435b
gmtOffSetMilliseconds§-18000000
targetHighPrice§115.0
targetLowPrice§50.0
targetMeanPrice§85.71
targetMedianPrice§89.0
recommendationMean§2.1
recommendationKey§buy
numberOfAnalystOpinions§17
quickRatio§3.821
grossMargins§0.91073
ebitdaMargins§-2.3765402
trailingPegRatio§None
